Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting
Observational Study
Diffuse Large B Cell Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a prospective and retrospective observational study. The primary objective is to identify new prognostic biomarkers for DLBCL patients in terms of progression-free survival (PFS) and able to add predictive capacity to recognized important clinical factors.
The secondary objectives are:
* to identify new biomarkers associated with overall survival (OS) and objective response rate (ORR)
* …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria for the prospective cohort:
* New diagnosis of High grade Diffuse large B cell Lymphoma undergoing first line standard treatment;
* Signed written informed consent;
* Availability of FFPE sample.
Inclusion Criteria for the retrospective cohort:
* Diagnosis of High grade Diffuse…
Contacts